![]() | ![]() |
Formats:
|
||||||||||||||||
A Multifunctional Single-Attachment-Point Reagent for Controlled Protein Biotinylation †Center for Molecular Imaging Research, Massachusetts General Hospital and Harvard Medical School, Building 149, 13th Street, Boston, MA 02129 (USA) ‡Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, 185 Cambridge Street, Boston, MA 02114 (USA) *Corresponding author: Center for Molecular Imaging Research, Massachusetts General Hospital and Harvard Medical School, Building 149, 13th Street, Boston, MA 02129 (USA), Phone: 617-726-6478, Fax: 617-726-5708, E-mail: ljosephson/at/mgh.harvard.edu The publisher's final edited version of this article is available at Bioconjug Chem.Abstract The biotin/avidin system is one of the most widely used affinity detection and affinity capture systems in biology. However, the determination of the exact number of biotin tags attached onto a substrate is complicated by the fact that biotin does not present any light-absorbing or -emitting properties. Here we describe a fluorescent biotinylation reagent designed from the general Multifunctional Single-Attachment-Point (MSAP) reagent concept. A Lys-Cys dipeptide scaffold was used to display a biotin functional group and a fluorescein functional group along with a N-Hydroxysuccinimide ester reactive group. The resulting bifunctional MSAP reagent, Fl-Biotin-NHS, was used to prepare a monobiotinylated version of cetuximab, which was further reacted with avidin to obtain a soluble avidin-based cetuximab oligomer. The MSAP peptide-scaffold approach allows fluorophores, chromophores or reactive groups to be combined with biotin and provides a broad approach to obtain multifunctional biotin-based reagents. INTRODUCTION The recognition of biotinylated molecules by avidin (or streptavidin) is one of the most widely exploited affinity capture systems in immunohistochemistry, biochemical purification, and in a variety of assay systems.(1) In many systems, where either avidin or biotin is immobilized, the capture is not highly sensitive to the number of biotins per mole of biotinylated protein. However, when the reaction between avidin and a biotinylated protein occurs in solution, the degree of biotinlylation of the protein is of considerable importance. The self-assembly of biotinylated proteins into avidin-mediated protein oligomers can produce profound changes in bioactivity, such as those which occur when biotinylated MHC molecules form streptavidin-based tetramers.(2) Reacting avidin with biotinylated proteins containing more than one biotin per mole can lead, not to tetramers, but to extended complexes of avidin and biotinylated proteins, which eventually precipitate (Figure 1A
We describe here a N-Hydroxysuccinimide (NHS) ester activated version of biotin and fluorescein, which can be used to determine the degree of biotinylation of proteins based on fluorescein’s absorbance or fluorescence. The reagent, termed “Fl-Biotin-NHS”, employed our multifunctional single-attachment-point (MSAP) technology(3), where fluorescein, biotin and the NHS ester are attached to a peptide scaffold. The Fl-Biotin-NHS reagent was used to obtain a monobiotinylated cetuximab that was further reacted with avidin to prepare a soluble avidin-based cetuximab oligomer. To demonstrate the flexibility of the MSAP peptide scaffold approach to reagent design, a second fluorescent biotin reacting with thiol groups, “Fl-Biotin-MAL” is also presented. EXPERIMENTAL PROCEDURE Synthesis of Biotin-Lys(monosuccinimidylsuberate)-Cys(5-acetamidofluorescein)-NH2, Fl-Biotin-NHS The linear Biotin-Lys(Boc)-Cys(Trt) sequence was elongated onto the Rink Amide MBHA resin using standard Fmoc/tBu solid phase peptide synthesis procedures described earlier.(3) Peptide full deprotection and cleavage from the resin with TFA/TIS/H2O/EDT (95:2:2:1) afforded the biotin-Lys(H)-Cys(H)-NH2 peptide as a white powder after lyophilization. (C19H34N6O4S2) Calc. exact mass: 474.2; found m/z: [M+H]+=475.1. Solutions of Biotin-Lys(H)-Cys(H)-NH2 (12.1 mg, 25.5 μmol) in 510 mL anhydrous DMF, fluorescein-5-iodoacetamide (8 mg, 15.5 μmol, 0.6 equiv.) in 155 μL anhydrous DMF and DIPEA (5 μL, 28.7 μmol, 1.1 equiv.) were mixed together overnight at room temperature. The reaction mixture was purified by RP-HPLC and the fraction collected lyophilized. Biotin-Lys(H)-Cys(5-acetamidofluorescein)-NH2 (8.4 mg, 9.7 μmol, 63% yield) was obtained as a yellow powder. (C41H47N7O10S2) Calc. exact mass: 861.3; found m/z: [M+H]+=862.0. A solution of Biotin-Lys(H)-Cys(5-acetamidofluorescein)-NH2 (5.9 mg, 6.8 μmol) in 274 μL anhydrous DMF containing DIPEA (1.3 μL, 7.5 μmol, 1.1 equiv.) was added slowly to a solution of DSS (50 mg, 135.7 μmol, 19.8 equiv.) in 1360 μL anhydrous DMF. The reaction mixture was stirred for 48 h at room temperature. The reaction mixture was purified by RP-HPLC and the fraction collected lyophilized. Biotin-Lys(monosuccinimidylsuberate)-Cys(5-acetamidofluorescein)-NH2 (5.2 mg, 4.7 μmol, 68% yield) was obtained as a yellow powder. (C53H62N8O15S2) Calc. exact mass: 1,114.4; found m/z: [M+H]+=1,115.0, [M+Na]+=1,137.0. Synthesis of Biotin-Lys(g-maleimidobutyryloxy)-Cys(5-acetamidofluorescein)-NH2, Fl-Biotin-MAL A solution of Biotin-Lys(H)-Cys(5-acetamidofluorescein)-NH2 (4.2 mg, 4.9 μmol) in 240 μL anhydrous DMF containing DIPEA (1.0 μL, 5.7 μmol, 1.2 equiv.) was added to a solution of GMBS (6.9 mg, 24.6 μmol, 5.1 equiv.) in 246 μL anhydrous DMF. The reaction mixture was stirred overnight at room temperature. The reaction mixture was purified by RP-HPLC and the fraction collected lyophilized. Biotin-Lys(g-maleimidobutyryloxy)-Cys(5-acetamidofluorescein)-NH2 (3.3 mg, 3.2 μmol, 66% yield) was obtained as a yellow powder. (C49H54N8O13S2) Calc. exact mass: 1,026.3; found m/z: [M+H]+=1,027.0, [M+Na]+=1,149.9. Biotinylation of cetuximab with Fl-Biotin-NHS Various amounts of a solution of Fl-Biotin-NHS in DMSO (10 mM) were added to Erbitux (2 mg/mL). Typically, 1.35 equiv. of reagent for a final degree of biotinylation of 1 were used. The reaction was left 1 h at room temperature and purified by size-exclusion chromatography using a Sephadex PD-10 column. Immunoconjugates were prepared in phosphate buffer pH 8 at 0.8 mg.mL-1. Absorbance measurements Absorption spectra were measured on a Varian Cary 50 Bio UV-Visible sprectrophotometer. Solutions of increasing concentrations of Fl-Biotin-NHS in phosphate buffer pH 8 were used to obtain a standard curve of optical density versus Fl-Biotin concentration. The absorbance was measured at the 493 nm absorbance maximum of Fl-Biotin-NHS. Solutions of cetuximab-(Fl-Biotin)n immunoconjugates were diluted two times. Absorbance was measured at 496 nm, absorbance maximum of cetuximab-(Fl-Biotin)n. Each measurement was repeated three times. The number of biotin tags for each immnunoconjugate was obtained from the standard curve. Fluorescence measurements Fluorescence emission spectra were recorded on a Varian Cary Eclipse fluorescence spectrophometer. Solutions of increasing concentrations of Fl-Biotin-NHS in phosphate buffer pH 8 were used to obtain the standard curve of fluorescence intensity at 519 nm versus Fl-Biotin concentration. Solutions of cetuximab-(Fl-Biotin)n immunoconjugates were diluted two times. Each measurement was repeated three times. The number of biotin tags for each immnunoconjugate was obtained from the standard curve. Preparation of the cetuximab:avidin oligomer A solution of Avidin-Cy3.51.4 (0.8 mg/mL ; 800μL, 10 nmol) in phosphate buffer pH 7.2 was added to a solution of cetuximab-Fl-Biotin1.1 (3.1 mg/mL ; 2.75 mL, 57 nmol). The mixture was stirred overnight at 4°C and purified by size exclusion chromatography using a Sephacryl 300-HR column volume=59.2 mL). The high valency was eluted in 34-40 mL phosphate buffer pH 7.2. Determination of the number of cetuximab in the cetuximab:avidin oligomer by absorbance Absorption spectrum (200-800 nm) of the cetuximab:avidin oligomer was measured in phosphate buffer pH 7.2. Absorbance at 583 nm gave the concentration of Cy3.5 in the complex (150,000 M-1.cm-1), without interference from fluorescein. Absorbance at 496 nm, corrected for the absorption of the Cy3.5 fluorochrome at this wavelength (18,000 M-1.cm-1), gave the concentration of fluorescein in the complex (74,000 M-1.cm-1). The ratio between fluorescein and Cy3.5 concentrations enabled an estimation of the number of cetuximab per avidin based on 1.1 Fl-Biotin per cetuximab and 1.4 Cy3.5 per avidin. Photon Correlation Spectroscopy Volume weighted average diameters were obtained by light scattering using a Nano-2S Zetasizer (Malvern Instruments). Solutions of (a) ferritin (1 mg/mL), (b) cetuximab (1 mg/mL), (c) avidin (1 mg/mL), (d) avidin (1 mg/mL)+ cetuximab (1 mg/mL), (e) cetuximab:avidin oligomer, were measured. “Native” gel electrophoresis “Native” SDS-PAGE was performed using a Tris-HCl gel from 4 to 15% polyacrylamide. Samples were prepared by using 20 μL of protein solution and 5 μL of a buffer containing Tris (25 mM), Glycine (192 mM), pH 8.3, 10% glycerol and bromophenol. Electrophoresis was run (from the anode to the cathode) with a buffer containing SDS (3.5 mM), Tris (25 mM) and Glycine (192 mM) at pH 8.3. No reducing Agent (β-mercaptoethanol) was used. RESULTS AND DISCUSSION The principles behind the MSAP reagent concept are shown in Figure 2
To demonstrate some of the flexibility possible with the peptide scaffold-based MSAP strategy, we prepared “Fl-Biotin-MAL”, where a maleimide RG replaced the NHS ester. Fl-Biotin-MAL becomes a site specific labeling reagent when reacted with bioengineered proteins containing a single thiol. The properties of Fl-Biotin-NHS and Fl-Biotin-MAL are given in Table 1. All subsequent experiments employed Fl-Biotin-NHS.
The Fl-Biotin-NHS MSAP, formally Biotin-Lys(monosuccinimidylsuberate)-Cys(5-acetamidofluorescein)-NH2, was synthesized as shown in Figure 3
Fl-Biotin-NHS was employed to prepare biotinylated versions of the monoclonal antibody cetuximab where the number of biotins varied from 0.1 to 2.5 per mole of antibody. Absorbance and fluorescence standard curves acquired with Fl-Biotin-NHS were used to determine the number of Fl-Biotin moieties per antibody. A perfect fit between the absorbance of the immunoconjugates and the amount of Fl-Biotin-NHS reagent used per cetuximab was obtained. The fluorescein absorption signal (496 nm) enabled to directly quantify a wide range of biotinylation levels. (Figure 4, A and C
In every case, we found both absorbance and fluorescence methods of Fl-Biotin more sensitive than the HABA method. (Figure 4, A and B We then considered the preparation of an avidin-based cetuximab oligomer from a monobiotinylated cetuximab and a tetrameric avidin. Fl-Biotin-NHS was thus used to modify cetuximab with 1.1 Fl-Biotin motifs per antibody. The latter was further incubated with avidin modified with the Cy3.5 fluorochrome. (Figure 5
An advantage of the MSAP synthetic strategy shown in Figure 3 CONCLUSION A peptide scaffold based, multifunctional, single-attachment-point reagent (MSAP) was used to obtain the fluorescent biotin, Fl-Biotin-NHS. Fl-Biotin-NHS was then used to attach 1.1 biotins per mole to cetuximab and the biotinylated antibody reacted with avidin to obtain an avidin-cetuximab oligomer. The Fl-Biotin-NHS can be used to biotinylate protein substrates with the degree of biotinylation determined by absorbance or fluorescence. In addition, MSAP reagents provide a broad new approach to the design of multifunctional biotins. Click here to view.(201K, doc) ACKNOWLEDGMENTS This work was supported by R01 EB004472, R01 EB00662 and P50 CA86355. Footnotes SUPPORTING INFORMATION AVAILABLE This information is available free of charge via the Internet at http://pubs.acs.org. LITERATURE CITED (1). Savage D, Mattson G, Desai S, Nielander G, Morgensen S, Conklin E. PIERCE Chemical Company Second Edition. 1994. Avidin-Biotin Chemistry: A Handbook. (2). Klenerman P, Cerundolo V, Dunbar PR. Tracking T cells with tetramers: new tales from new tools. Nat. Rev. Immunol. 2002;2:263–72. [PubMed] (3). Garanger E, Weissleder R, Josephson L. Simplified syntheses of complex multifunctional nanomaterials. Chem. Commun. 2008;(39):4792–4. |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||
Nat Rev Immunol. 2002 Apr; 2(4):263-72.
[Nat Rev Immunol. 2002]